Alem Truneh
Gastroenterology
Imcheck Therapeutics
France
Biography
Dr. Alem Truneh, Ph.D. co-founded ImCheck Therapeutics in 2015 and is the Chief Technology Officer of the company. Previously, Dr. Alem Truneh co-founded NKT Therapeutics, Inc. in 2011 and served as its Chief Scientific Officer and Executive Vice President of Research & Development. He is today a member of the Scientific Advisory Board of this company. Mr. Truneh is a senior pharmaceutical executive with over 25 years of experience in biomedical R&D. Dr. Truneh spent 17 years at GlaxoSmithKline (GSK) where he helped advance several products, biologics, as well as small molecule drugs, from early discovery through advanced clinical trials, and post-market product differentiation and line extensions. Dr. Truneh spent over 4 years as Vice President and Senior Vice President of R&D at Antigenics and TolerRx, respectively, where he oversaw programs in cancer, autoimmune and allergic disorders and infectious diseases. Dr. Truneh was Founder and President of Synaptex, Inc., a company focused on the discovery and development of biologics therapies for the treatment of cancer and autoimmune diseases through targets at the immune synapse. He has been a visiting scientist at INSERM/CNRS in France, a fellow of the European Molecular Biology Organization, and Associate Professor of Pharmacy at Marseille University. Dr. Truneh has co-authored over 100 scientific papers and is co-inventor on 30 patents. Dr. Truneh obtained his B.Sc. and Ph.D. in Biochemistry from the University of London.
Research Interest
Dr. Alem Truneh, Ph.D. co-founded ImCheck Therapeutics in 2015 and is the Chief Technology Officer of the company. Previously, Dr. Alem Truneh co-founded NKT Therapeutics, Inc. in 2011 and served as its Chief Scientific Officer and Executive Vice President of Research & Development. He is today a member of the Scientific Advisory Board of this company. Mr. Truneh is a senior pharmaceutical executive with over 25 years of experience in biomedical R&D. Dr. Truneh spent 17 years at GlaxoSmithKline (GSK) where he helped advance several products, biologics, as well as small molecule drugs, from early discovery through advanced clinical trials, and post-market product differentiation and line extensions. Dr. Truneh spent over 4 years as Vice President and Senior Vice President of R&D at Antigenics and TolerRx, respectively, where he oversaw programs in cancer, autoimmune and allergic disorders and infectious diseases. Dr. Truneh was Founder and President of Synaptex, Inc., a company focused on the discovery and development of biologics therapies for the treatment of cancer and autoimmune diseases through targets at the immune synapse. He has been a visiting scientist at INSERM/CNRS in France, a fellow of the European Molecular Biology Organization, and Associate Professor of Pharmacy at Marseille University. Dr. Truneh has co-authored over 100 scientific papers and is co-inventor on 30 patents. Dr. Truneh obtained his B.Sc. and Ph.D. in Biochemistry from the University of London.
